Duration of ibrutinib treatment
| . | Ibrutinib, n = 135∗ . |
|---|---|
| Duration of ibrutinib treatment, median (range), y | 6.2 (0.06-10.2) |
| Continuing ibrutinib at study closure, n (%) | 37 (27) |
| Reason for ibrutinib discontinuation, n (%) | |
| AE | 44 (33) |
| PD | 18 (13) |
| Death | 12 (9) |
| Withdrawal of consent for treatment by patient | 13 (10) |
| Investigator decision | 11 (8) |
| . | Ibrutinib, n = 135∗ . |
|---|---|
| Duration of ibrutinib treatment, median (range), y | 6.2 (0.06-10.2) |
| Continuing ibrutinib at study closure, n (%) | 37 (27) |
| Reason for ibrutinib discontinuation, n (%) | |
| AE | 44 (33) |
| PD | 18 (13) |
| Death | 12 (9) |
| Withdrawal of consent for treatment by patient | 13 (10) |
| Investigator decision | 11 (8) |
One additional patient was randomly assigned to the ibrutinib arm but did not receive any doses of ibrutinib.